Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Search jobs 01-Jun-2021 Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis
- NDA supported by positive data from VIOLET and ultraVIOLET Phase 3 clinical trials evaluating oteseconazole in more than 870 women in 11 countries -
- Oteseconazole’s Qualified Infectious Disease Product and Fast-Track designations allow for six-month priority review by FDA following its acceptance of the NDA -
DURHAM, N.C. (BUSINESS WIRE) Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced it has submitted its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC). Also known as chronic yeast infection, RVVC is a debilitating inf
Come and apply the insights recommended by the honchos of the Candidiasis Therapeutics industry.
Candidiasis Therapeutics Market Report, published by Decisive Markets Insights, provides granular information & analysis on the size, share, growth patterns, segment and forecast of the market from, 2020 – 2027.The report covers the rapidly evolving market scenario and the current and future evaluation of their impact on the overall industry along with regional coverage across the globe. With an in-depth report on sales growth and profitability, it also covers the accurate trend and analysis that would impact the market in the coming years. The analysis provides key players, a competitive perspective so as to formulate their business strategies accordingly.
Published: Jan 06, 2021
- Efficacy of Oteseconazole Compared to Fluconazole in Treating Acute VVC Infection in Women with RVVC -
- NDA Submission Planned in First Half of 2021 -
DURHAM, N.C. (BUSINESS WIRE) Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced positive topline results from its Phase 3 clinical trial for oteseconazole (ultraVIOLET), its drug candidate for treating patients with recurrent vulvovaginal candidiasis (RVVC). RVVC, commonly known as chronic yeast infection, is a debilitating infectious condition defined as three or more episodes per year. Oteseconazole is designed to be highly selective for its pathogenic target, with fewer side effects and improved efficacy over current treatment options, including the current standard of care for vulvovaginal candidiasis (VVC), fluconazole.